Anti-Human Beta-Defensin-3-Biotin

E. coli-Derived Recombinant Human BMP-2

This biotinylated antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 50 µg of bovine serum albumin per µg of antibody with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized, biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted bioin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 5-15 µg/ml. The recommended secondary antibody for IHC is PN:A106. For chromogenic detection with high signal and low background use PN:D100 or PN:K107.

Goat Anti-Human Beta-Defensin-3 (BD-3) recognizes Human BD-3. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

β-Defensin 3, also known as BD3 and DEFB-3, is a membrane-active cationic peptide that functions in inflammation and innate immune responses. There are at least 30 beta-Defensins which are distinguished from alpha-Defensins by the connectivity pattern of their three intramolecular disulfide bonds. The 45 aa mature human BD3 shares 38% and 33% aa sequence identity with mouse and rat BD3, respectively. It shares 18% - 36% aa sequence identity with other human beta-Defensins. BD3 is widely expressed among epithelial tissues, notably by keratinocytes and airway epithelial cells. It is upregulated in response to proinflammatory cytokines, microbial and viral infections, and at the edges of skin wounds. BD3 induction in osteoarthritis chondrocytes promotes MMP1 and 13 production and inhibits TIMP1 and 2 expression. In vivo control of BD3 activity is accomplished in part through cleavage by cathepsins B, L, and S. BD3 displays strain specific microbicidal activity toward a broad spectrum of bacteria and yeast. BD3 also induces monocyte migration, mast cell activation, and a mast cell-dependent increase in vascular permeability. Disruption of the intramolecular disulfide bond pattern in BD3 abrogates its monocyte chemoattractant properties but not its antimicrobial properties.

BD3 inhibits viral infectivity by interacting directly with HIV-1 plus its coreceptor CXCR4, and with HSV glycoprotein B plus its receptor heparan sulfate , and by forming a protective coating on the surface of influenza virus target cells.